MONDAY, Aug. 25, 2025 (HealthDay News) -- The U.S. Food and Drug Administration is suspending the biologics license for the live-attenuated chikungunya vaccine, Ixchiq, in the United States. The move comes after reports of serious side effects in older adults similar to the symptoms of chikungunya virus.

Chikungunya virus is a mosquito-borne disease causing fever, rash, headache, nausea, fatigue, and severe joint and muscle pain, which can be long-lasting and debilitating.

The FDA granted accelerated approval of Ixchiq in November 2023 to prevent chikungunya virus in adults 18 years and older with an increased risk for exposure.

However, according to the FDA Vaccine Adverse Event Reporting System, Ixchiq has been linked to one confirmed encephalitis death, more than 20 serious adverse e

See Full Page